Huvepharma announced that the first Food & Drug Administration-approved generic monensin — available to U.S. beef, dairy and goat producers as Monovet 90 from Huvepharma — has now also received FDA approval for combination use with other drug feed additive products in the manufacture of Type B and Type C medicated feeds.
Monovet 90, the generic equivalent to Rumensin 90, is an ionophore that alters rumen fermentation patterns to increase feed efficiency, particularly among feedlot cattle, and to improve the bodyweight gain of cattle on pasture, the company said. The combination approvals allow Monovet 90 to be used with other feed additives commonly fed to feedlot cattle, such as tylosin, ractopamine and melengestrol. Huvepharma said a list of current medicated feed combinations approved with Monovet 90 is available at https://www.monovet.us.
“By bringing the first generic monensin product in the marketplace, Huvepharma offers livestock producers a new cost-effective choice while providing the same benefits of dosage, chemical identity, potency, quality, safety and route of administration,” Huvepharma US president Glen Wilkinson said.
Wilkinson noted that Huvepharma has a vertically integrated infrastructure in fermentation production that facilitates its core strength in manufacturing medicated feed additives and other critical products for the animal food producing industry.
Huvepharma has been active in the U.S. animal health market since its inception in 2005, providing products for poultry, swine and cattle markets. The company received FDA approval for Monovet 90 in the U.S. in July 2019, which follows a generic approval for tylosin phosphate, sold as Tylovet.
Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. It is a privately owned company headquartered in Sofia, Bulgaria, with U.S. headquarters located in Peachtree City, Ga.